



an Open Access Journal by MDPI

Diagnosis for SARS-CoV-2 Infections

Guest Editors:

Dr. Rajiv Pathak

Department of Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 823 Bronx, New York, NY 10461, USA

Dr. Prajna Tripathi

Microbiology and Immunology, Weill Cornell Medical College, New York, NY 14853, USA

Deadline for manuscript submissions:
closed (29 February 2024)

Message from the Guest Editors

Dear colleagues,

This Special Issue of MPDI's *Vaccines* focuses on the recent advances and future prospects in the field of SARS-CoV-2 diagnosis. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Rapid, sensitive, specific, and scalable diagnosis and monitoring of SARS-CoV-2 infections.
- Limitations of current diagnostic testing and recent developments in the field of SARS-CoV-2 diagnosis to identify specific variants of concern.
- Serodiagnostic tests and their effectiveness for diagnosing SARS-CoV-2 infection
- The role of antibodies in SARS-CoV-2 diagnosis
- Plasma levels of pro-inflammatory and anti-inflammatory cytokines associated with the progression and severity of SARS-CoV-2 infection.
- Underlying host immune responses against SARS-CoV-2 infection.
- Specific immunological responses and inflammatory markers distinguishing SARS-CoV-2 infection from clinically similar non-COVID-19 viral infections.

We look forward to receiving your contributions.



mdpi.com/si/159092

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:— free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com